A Phase I/II Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With Metastatic Renal Cell Carcinoma.

Trial Profile

A Phase I/II Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With Metastatic Renal Cell Carcinoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Sep 2014

At a glance

  • Drugs Siltuximab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jun 2014 Protocol has been amended with a change in primary outcome measures.
    • 19 Oct 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top